Skip to main content
. 2024 Feb 6;16(4):680. doi: 10.3390/cancers16040680

Figure 4.

Figure 4

Combinatorial approaches to using epigenetic enzyme inhibitors and topo-active drugs for enhanced drug responsiveness. Topoisomerase I (TOPI), topoisomerase II (TOPII), and topoisomerase inhibitors (topo inhibitors); histone deacetylase inhibitor (HDACi).